InsidersTradesSigma
Follow the MACROGENICS, INC. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €259.9m. The latest transaction was disclosed on 17 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Jay Siegel. Every trade is openly available.
Analysts rate MACROGENICS, INC. Buy (bullish), based on 4 analysts. Average price target: US$7.25.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
3 of 3 declarations
MACROGENICS, INC. 是一家生物制药公司，专注于开发创新的癌症治疗方法。该公司在纳斯达克上市，股票代码为 MGNX。